New anti-diabetic agents
Journal of the Korean Medical Association
;
: 992-997, 2017.
Artigo
em Coreano
| WPRIM
| ID: wpr-158094
ABSTRACT
Diabetes mellitus is characterized by hyperglycemia due to insulin deficiency and/or insulin resistance. Cardiovascular disease (CVD) is a major comorbidity of type 2 diabetes mellitus, and is the most common cause of death in people with diabetes mellitus. Several clinical trials have addressed the long-term effects of near-normoglycemia on CVD, but did not find evidence of an effect. However, some recent clinical trials of sodium glucose cotransporter 2 inhibitors (EMPA-REG [Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes Trial], CANVAS [Canagliflozin Cardiovascular Assessment Study]) or glucagon-like peptide-1 agonists (LEADER [Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation], SUSTAIN-6 [Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes]) showed very promising results regarding the prevention of CVD. In this review, I discuss some of these new anti-diabetic agents and present clinical information regarding these drugs.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Sódio
/
Resistência à Insulina
/
Doenças Cardiovasculares
/
Comorbidade
/
Mortalidade
/
Causas de Morte
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Peptídeo 1 Semelhante ao Glucagon
/
Glucose
Tipo de estudo:
Estudo prognóstico
Idioma:
Coreano
Revista:
Journal of the Korean Medical Association
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS